Ghana’s Food and Drugs Authority (FDA) has approved a malaria vaccine developed by the University of Oxford for use in children aged 5 months to 3 years.
Manufactured by the Serum Institute of India, the R21/Matrix-M malaria vaccine contains the circumsporozoite protein, secreted by the malaria parasite, fused to hepatitis B surface antigen, and delivered alongside Novavax’s Matrix-M adjuvant, which stimulates the entry of antigen presenting cells …